

AGE Reader

Worldwide experience, Key customers &
Reference centers



AGE
READER **mu**
Know their risk.



AGE
READER **SU**
Know their risk.

Worldwide experience

- Available worldwide. Distributors in 20 countries → visit www.diagnoptics.com for an overview of all distributors.
- >130 peer-reviewed AGE Reader publications in international journals, such as:
 - Diabetologia
 - Diabetes
 - Diabetes Care
 - ATVB (Arteriosclerosis, Thrombosis and Vascular Biology)
 - Atherosclerosis
- Worldwide installed base: 2000 units

Summary of key customers

Europe

- University Medical Center Groningen, Groningen, the Netherlands.
- LifeLines Cohort Study Group, the Netherlands
- Maastricht University Medical Center+, Maastricht, The Netherlands.
- University of Bordeaux, France.
- University Hospital Halle, Halle (Saale), Germany.
- Royal Derby Hospital National Health Service Foundation Trust, Derby, Derbyshire, United Kingdom
- Poznan University of Medical Sciences, Poznan, Poland.
- Edouard Herriot Hospital, Lyon, France.

Summary of key customers

Asia

- Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
- Zhejiang University College of Medicine, Hangzhou, China.
- Southern Clinical School, Monash University, Melbourne, Victoria, Australia.
- St Vincent's Hospital, Melbourne, Australia.
- Tohoku University Graduate School of Medicine, Sendai, Japan.
- Fukushima Medical University, Fukushima, Japan

Middle-east:

- American Hospital, Dubai, United Arab Emirates.

American Hospital, Dubai

Dr. Hubert Penninckx
Specialist Endocrinologist & Diabetologist



Delivering better health in the Middle East

“Checking AGE values gives extra information about the past glycemc regulation of patients, certainly when you see them for the first time after 10-15 years of the start of their treatment by other doctors

The result of the test helps me also in the motivation for the good results to go on with their ‘good’ treatment and for the people with higher AGE values to change the diabetes treatment – e.g. stop smoking, increasing statins, making better blood pressure treatment and switch to more intensive diabetes treatment like GLP1 injections or multiple therapy.

A high AGE result will make that I will go also more quickly for more intensive control for heart and blood vessel with stress-echocardio and duplex of carotic arteries – even so without specific symptoms and more specific in typ1 DM women.”

Sana-Klinikum, Remscheid, Germany

A. Stirban, MD PhD

**Specialist in Internal Medicine,
Diabetology and Endocrinology**



“The AGE Reader allows a quick and non-invasive assessment of the accumulation in skin of the so-called advanced glycation endproducts (AGEs). Their enhanced production and accumulation correlates with an increased cardiovascular risk and the risk for the development of diabetic complication. Thus, the AGE Reader can be used alone or in addition to other well-established tools to identify patients at risk.”

Maastricht UMC+, the Netherlands

Prof. dr. C. Schalkwijk

Professor of Experimental Internal Medicine

Maastricht UMC+



academisch ziekenhuis
Maastricht



Maastricht University

“The AGE Reader gives a quick and reliable assessment of fluorescent levels in tissue. The AGE Reader SU is a convenient tool for both subject and operator. We have used this technology as a noninvasive marker for tissue AGEs in large study cohorts for several years now and are very satisfied with its performance.

We recently found inverse associations of AGE Reader measurements with cognitive performance. We will continue measuring skin autofluorescence with the AGE Reader in the next few years and expect to publish our results in international peer-reviewed journals.”